Skip to main content

Advertisement

SpringerLink
Log in

Effects of chronic hyperinsulinemia in insulin-resistant patients

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Selective insulin resistance influences pathogenesis and treatment of type 2 diabetes and metabolic syndrome. Downregulation of the antiatherogenic pathway and maintained activity of the proatherogenic and cancerogenic pathways lead to atherosclerosis and cancer. Exogenous insulin added to “compensatory” hyperinsulinemia might worsen the primary end points, resulting in potential increase in cardiovascular and cancer events in spite of improvement of surrogate metabolic end points. Conversely, metformin can improve primary and surrogate end points.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 2003, 37:1595–1607.

    Article  Google Scholar 

  2. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15:318–368.

    Article  PubMed  CAS  Google Scholar 

  3. Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects PI 3-kinase and MAP-kinase-mediated signalling in human muscle. J Clin Invest 2000, 105:311–320.

    Article  PubMed  CAS  Google Scholar 

  4. Montagnani M, Golovchenco I, Kim I, et al.: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002, 277:1794–1799.

    Article  PubMed  CAS  Google Scholar 

  5. Wang CCL, Goalstone ML, Draznin B: Molecular mechanism of insulin resistance that impact cardiovascular biology. Diabetes 2004, 53:2735–2740.

    Article  PubMed  CAS  Google Scholar 

  6. Draznin B: Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85? The two sides of a coin. Diabetes 2006, 55:2392–2397.

    Article  PubMed  CAS  Google Scholar 

  7. Giovannucci E: The role of insulin resistance and hyperinsulinemia in cancer causation. Curr Med Chem-Immun Endoc & Metab Agents 2005, 5:53–60.

    Article  CAS  Google Scholar 

  8. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425–430.

    Article  PubMed  CAS  Google Scholar 

  9. Ness GC, Chambers CM: Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000, 224:8–19.

    Article  PubMed  CAS  Google Scholar 

  10. Siperstein MD: Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 1984, 25:1462–1468.

    PubMed  CAS  Google Scholar 

  11. Muis MJ, Bots ML, Grobbee DE, Stolk RP: Insulin treatment and cardiovascular disease: friend or foe? A point of view. Diabet Med 2004, 22:118–126.

    Article  Google Scholar 

  12. Stettler C, Alleman S, Jüni P, et al.: Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006, 152:27–38.

    Article  PubMed  CAS  Google Scholar 

  13. Garcia MJ, McNamara P, Gordon T, Kannell WB: Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23:105–111.

    PubMed  CAS  Google Scholar 

  14. Janka HU, Ziegler AG, Standl E, Menhert H: Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabete Metab 1987, 13:359–364.

    PubMed  CAS  Google Scholar 

  15. Kleinman JC, Donahue RP, Harris M, et al.: Mortality among diabetics in a national sample. Am J Epidemiol 1988, 128:389–401.

    PubMed  CAS  Google Scholar 

  16. Nelson RG, Sievers ML, Knowler WC, et al.: Low incidence of coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990, 81:987–995.

    PubMed  CAS  Google Scholar 

  17. Muggeo M, Verlato G, Bonora E, et al.: The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia 1995, 38:318–325.

    Article  PubMed  CAS  Google Scholar 

  18. Colwell J, Abraira C, Henderson W, et al.: VA Cooperative Study on glycemic control and complications in type II diabetes (VACSDM): micro and macrovascular events. Diabetologia 1996, 39(Suppl 1):A34.

    Google Scholar 

  19. Abraira C, Colwell J, Nuttall F, et al.: Cardiovascular events and correlates in the Veteran Affairs Diabetes Feasibility Trial. Veteran Affairs Cooperative Study on glycemic control and complications in type II diabetes. Arch Intern Med 1997, 7:181–188.

    Article  Google Scholar 

  20. Faglia E, Favales F, Quarantiello A, et al.: are insulin-treated type 2 subjects at higher risk for foot ulcers? Diabetes Care 1999, 22:1379–1380.

    Article  Google Scholar 

  21. Bruno G, Merletti F, Boffetta P, et al.: Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of Type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:297–301.

    Article  PubMed  CAS  Google Scholar 

  22. Saito I, Folsom AR, Brancati FL, et al.: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis risk in communities (ARIC) study. Ann Intern Med 2000, 133:81–91.

    PubMed  CAS  Google Scholar 

  23. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl 2):B21–B29.

    PubMed  Google Scholar 

  24. Nichols GA, Gullion CM, Koro CE, et al.: Risk of congestive heart failure after initiation of anti-hyperglycemic therapy. Diabetologia 2003, 46:A364.

    Google Scholar 

  25. Kronmal RA, Barzilay JI, Tracy RP, et al.: The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab 2004, 89:2852–2858.

    Article  PubMed  CAS  Google Scholar 

  26. Smooke S, Horwich TB, Fonarow GC: Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005, 149:168–174.

    Article  PubMed  CAS  Google Scholar 

  27. Tseng C-H: Exogenous insulin use and hypertension in adult patients with diabetes mellitus. Arch Intern Med 2006, 166:1184–1189.

    Article  PubMed  Google Scholar 

  28. Kronmal RA, Barzilay JL, Smith NL, et al.: Mortality in pharmacologically treated older adults with diabetes: the Cardiovascular Health Study 1989–2001. PLoS Med 2006, 3:e400.

    Article  PubMed  Google Scholar 

  29. Yang YX, Hennessy S, Lewis JD: Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004, 127:1044–1050.

    Article  PubMed  CAS  Google Scholar 

  30. Renehan AG, Shalet SM: Diabetes, insulin therapy, and colorectal cancer [editorial]. BMJ 2005, 330:551–552.

    Article  PubMed  Google Scholar 

  31. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 23:441–442.

    Google Scholar 

  32. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 31:281–303.

    Google Scholar 

  33. Ballani P, Tran MT, Navar MD, Davidson MB: Clinical experience with U-500 regular insulin in obese, markedly insulin resistant type 2 diabetic patients. Diabetes Care 2006, 29:2504–2505.

    Article  PubMed  CAS  Google Scholar 

  34. Gerstein HC: Glycosylated haemoglobin: finally ready for prime time as cardiovascular risk factor. Ann Intern Med 2004, 141:475–476.

    PubMed  CAS  Google Scholar 

  35. Dandona P, Aljada A, Mohanty P: The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002, 45:924–930.

    Article  PubMed  CAS  Google Scholar 

  36. Dandona P, Aljada A, Mohanty P, et al.: Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 2003, 26:3310–3314.

    Article  PubMed  CAS  Google Scholar 

  37. Madonna R, Pandolfi A, Massaro M, et al.: Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004, 47:532–536.

    Article  PubMed  CAS  Google Scholar 

  38. Rossouw JE, Anderson GL, Prentice RL, et al.: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333.

    Article  PubMed  CAS  Google Scholar 

  39. Lenzer J: FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 2005, 330:440.

    Article  PubMed  Google Scholar 

  40. Herrington DM, Howard TD: From presumed benefit to potential harm—hormone therapy and heart disease. N Engl J Med 2003, 349:519–521.

    Article  PubMed  Google Scholar 

  41. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854–865.

    Article  Google Scholar 

  42. Zhou G, Myers R, Li Y, et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167–1174.

    PubMed  CAS  Google Scholar 

  43. Muntoni S: Inhibition of fatty acid oxidation by biguanides: implications for metabolic physiopathology. Adv Lipid Res 1974, 12:311–377.

    PubMed  CAS  Google Scholar 

  44. Muntoni S: Metformin and fatty acids. Diabetes Care 1999, 22:179–180.

    Article  PubMed  CAS  Google Scholar 

  45. Essop MF, Opie LH: Metabolic therapy for heart failure. Eur Heart J 2004, 25:1765–1768.

    Article  PubMed  Google Scholar 

  46. Muntoni S: Metformin and heart failure: innocent until proven guilty. Diabetes Care 2006, 29:751–752.

    Article  PubMed  Google Scholar 

  47. von Lewinski D, Bruns S, Walther S, et al.: Insulin causes [Ca2+]i-dependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium. Circulation 2005, 111:2588–2595.

    Article  Google Scholar 

  48. Gandhy GY, Nuttall GA, Abel MD, et al.: Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 2007, 146:233–243.

    Google Scholar 

  49. Muntoni S, Muntoni SA: Insulin treatment in the absence of dependence. Available at http://www.annals.org/cgi/eletters/146/4/233#15139. Accessed February 28, 2008.

Download references

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center, ACOS for R&D, Denver VA Medical Center, 1055 Clermont Street, Denver, CO, 80220, USA

    Boris Draznin

Authors
  1. Sergio Muntoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandro Muntoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boris Draznin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Draznin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muntoni, S., Muntoni, S. & Draznin, B. Effects of chronic hyperinsulinemia in insulin-resistant patients. Curr Diab Rep 8, 233–238 (2008). https://doi.org/10.1007/s11892-008-0040-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-008-0040-z

Keywords

Search

Navigation